Based on the advantages of heparin APIs, expanding towards the downstream preparations

Enhancing the core competitive power of the anticoagulation market segment 

Build a preparation brand well-known at home and abroad

        In 2013, the board of directors of the company put forward the development strategy of “endogenous growth and extensive expansion”, which required to expand towards the new business of preparations based on the the advantages of heparin APIs. In just nine months, Dongcheng Biopharmaceutical Industrial Park as the platform for developing the preparation business rose up straight from the grounds and laid a solid foundation for the improvement of the company’s core competitive power. 

      At present, the preparation sector has two wholly-owned subsidiaries under the “industrial park”, namely Dongcheng Beifang and Dongcheng Dayang, which mainly produce lyophilized powder injections, hard capsules, tablets, granules and drilling pills, and cover the therapeutic areas such as cardiovascular, anti-tumor, urology, orthopedics and anti-infection. The anticoagulation product “Bailishu” nadroparin calcium for injection is the only powder injection and small dose of low-molecular calcium heparin in China. In 2019, its sales revenue exceeded RMB600 million and became the leading brand in the anticoagulation segment. 

      The company’s preparation business sector will be based on the advantages of heparin APIs, continuously expand towards the downstream preparations, constantly enhance core competitive power on the anticoagulation niche market, and build a preparation brand well-known at home and abroad.